Efficacy of Drug and Risk Behavior Counseling Intervention Among Injecting Drug Users at Opioid Substitution Treatment
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Substance Use Disorders
- Sponsor
- National Taiwan University
- Enrollment
- 118
- Primary Endpoint
- Change in heroin use
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Behavior drug and risk reduction counseling (BDRC), a structured, non-intense, cognitive-behavioral approach intervention designed to increase methadone maintenance treatment retention and reduce drug use and related risk behaviors among IDUs.
Detailed Description
Techniques of the Cognitive Behavior Therapy combined with drug dependence psychoeducation was developed by research team. BDRC consists of 12 sessions, including an initial session, 3 drug education sesssions, psychosocial counseling and behavioral skills. This initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach. Drug education focuses on how heroin may influence patients' cognitive function and their HIV/HCV risk behaviors. Counseling and behavior skills trained patients to reflect their thoughts and learned new life skills in order to delay or abstrain from heroin use.
Investigators
Tony Szu-Hsien Lee
Professor
National Taiwan University
Eligibility Criteria
Inclusion Criteria
- •Enrollment in opioid substitution treatment
- •Injected heroin within past 30 days by self-report, documented by "tracks" or puncture marks
- •20 or more years of age
- •Meets ICD-10 criteria for opiates dependence with physiologic features
- •Agrees to keep bi-weekly appointments if selected
- •Current address within Taipei and Keelung, and not planning to move
- •Willingness and ability to give informed consent and otherwise participate
- •Provision of adequate locator information
Exclusion Criteria
- •Clinically significant cognitive impairment, schizophrenia, paranoid disorder, bipolar disorder
- •Advanced neurological, cardiovascular, renal, or other medical disorder that is likely to impair or make hazardous patient's ability to participate
- •Physiologically dependent on alcohol, benzodiazepines or other sedative type drugs
- •Concurrent participation in another treatment study
- •Planning to enter inpatient or residential treatment within next year
- •Pending legal charges with likely incarceration within next 12 months
Outcomes
Primary Outcomes
Change in heroin use
Time Frame: 3, 6, and 12 months
Testing patients' urine for heroin use
Secondary Outcomes
- Number of treatment section(Within 6 months)